For some time, we’ve been tracking the Harvard/MGH clinical study currently assessing the efficacy of vitamin supplement Nicotinamide Riboside “NR” (FAQs) (Reviews) in alleviating some of the symptoms associated with “long haul COVID”. In a presentation this past week entitled “A Randomized Placebo Controlled Parallel Group Clinical Trial testing the impact of Nicotinamide Riboside (NR) on NAD+ Levels and Long COVID symptom recovery: Preliminary Baseline Findings“, Harvard’s Dr. Edmarie Guzmán-Vélez shared some of her preliminary findings. We encourage you to watch the presentation in its entirety (video embedded below). If you don’t have time, here are some key quotes:
Month: March 2022
In a wide-ranging Twitter Q&A yesterday, Dr. Charles Brenner, who discovered Nicotinamide Riboside “NR” (FAQs) (Reviews) as an NAD+ boosting vitamin was asked about how to measure NAD+ levels. Here’s what he said:
We know there’s significant interest in NAD+ boosting vitamin supplement Nicotinamide Riboside “NR” (FAQs) (Reviews) as a potential treatment for Alzheimer’s Disease (Link). It appears the same can now be said for NR and Parkinson’s. The following are results of a Phase 1 clinical trial published yesterday (Note: A Phase 2 study is already underway):